May 26, 2026 10:00AM
May 26, 2026 10:00AM
May 7, 2026 04:01PM
May 1, 2026 07:30AM
May 1, 2026 07:30AM
Apr 24, 2026 06:39AM
Apr 24, 2026 06:39AM Arrowhead Pharmaceuticals Receives Positive CHMP Opinion Recommending Approval of REDEMPLO® (plozasiran) to Reduce Triglycerides in Adults with Familial Chylomicronemia Syndrome (FCS) in Europe
Mar 30, 2026 04:21AM
Mar 28, 2026 10:30AM
Mar 26, 2026 02:33PM
Feb 17, 2026 08:30AM
Feb 5, 2026 04:05PM
Jan 7, 2026 07:32AM
Jan 7, 2026 07:30AM Arrowhead Pharmaceuticals Announces NMPA Approval of REDEMPLO® (plozasiran) for Familial Chylomicronemia Syndrome (FCS) in China
Jan 5, 2026 07:30AM
Jan 5, 2026 07:30AM
Dec 22, 2025 07:06AM
Dec 21, 2025 04:00AM
Dec 19, 2025 09:06AM
Dec 2, 2025 07:30AM
Dec 2, 2025 07:30AM Arrowhead Pharmaceuticals Receives FDA Breakthrough Therapy Designation for Plozasiran in Severe Hypertriglyceridemia
Nov 25, 2025 04:00PM
Nov 19, 2025 09:14AM
Nov 19, 2025 09:06AM
Nov 19, 2025 08:51AM
Nov 18, 2025 11:52AM
Nov 18, 2025 11:52AM
Nov 18, 2025 11:17AM FDA approves Arrowhead's Redemplo to reduce triglycerides in adults with familial chylomicronemia syndrome
Oct 24, 2025 08:29AM
Sep 11, 2025 07:30AM
Sep 11, 2025 07:30AM
Aug 7, 2025 04:01PM
Aug 1, 2025 06:30AM
Aug 1, 2025 06:30AM
Jun 23, 2025 07:30AM Arrowhead Pharmaceuticals Completes Enrollment in SHASTA-3, SHASTA-4, and MUIR-3 Phase 3 Studies of Plozasiran
May 13, 2025 04:52AM
May 12, 2025 04:01PM
Feb 10, 2025 04:01PM
Jan 17, 2025 04:30PM
Jan 3, 2025 07:33AM
Dec 4, 2024 06:47AM
Nov 27, 2024 07:14AM Chardan Capital Markets Reiterates Buy Rating on Arrowhead Pharma (ARWR)
Nov 27, 2024 05:33AM
Nov 26, 2024 04:00PM
Nov 26, 2024 07:00AM
Nov 18, 2024 01:58PM
Nov 18, 2024 07:31AM
Nov 18, 2024 07:31AM
Nov 18, 2024 07:31AM Arrowhead Pharmaceuticals Submits New Drug Application to U.S. FDA for Plozasiran for the Treatment of Familial Chylomicronemia Syndrome
Nov 18, 2024 07:30AM

323,324 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All